Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity

Author(s):Show less -

Claudino Formiga, Francisco Fellipe ^[1] ; Silva, Clovis Artur ^[2] ; Pedrosa, Tatiana do Nascimento ^[1] ; Aikawa, Nadia Emi ^[2] ; Pasoto, Sandra Gofinet ^[1] ; Garcia, Cristiana Couto ^[3] ; Vidal Capao, Artur Silva ^[3] ; de Oliveira Martins, Victor Adriano ^[1] ; Tonacio de Proenca, Adriana Coracini ^[4] ; Fuller, Ricardo ^[1] ; Neves Yuki, Emily Figueiredo ^[1] ; Galhardo Vendramini, Margarete Borges ^[1] ; do Rosario, Debora Cordeiro ^[1] ; Kolachinski Raposo Brandao, Leticia Maria ^[1] ; Christovam Sartori, Ana Marli ^[4] ; Antonangelo, Leila ^[5] ; Bonfa, Eloisa ^[1] ; Borba, Eduardo Ferreira ^[1]

Affiliation

^[1] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Rheumatol Div, Av Dr Arnaldo 455, 3 Floor, Room 3190, BR-01246903 Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Pediat Rheumatol Unit, Sao Paulo - Brazil

^[3] Fiocruz MS, Lab Resp Virus & Measles, Inst Oswaldo Cruz, Rio De Janeiro - Brazil

^[4] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Infect & Parasit Dis, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Clin Lab Div, Dept Pathol, Sao Paulo - Brazil

• Document type: Journal article
• Source: Lupus; v. 30, n. 12 AUG 2021.
• Web of Science Citations: 0

Abstract

Introduction Influenza A (H3N2) virus is the most important cause of seasonal influenza morbidity and mortality in the last 50 years, surpassing the impact of H1N1. Data assessing immunogenicity and safety of this virus component are lacking in systemic lupus erythematosus (SLE) and restricted to small reports with other H3N2 strains. Objective This study aims to evaluate short-term immunogenicity and safety of influenza A/Singapore (H3N2) vaccine in SLE. Methods 81 consecutive SLE patients and 81 age- and sex-matched healthy controls (HC) were vaccinated with the influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus. Seroprotection (SP) and seroconversion (SC) rates, geometric mean titers(GMT), and factor increase in GMT(FI-GMT) and adverse events were assessed before and 4 weeks post-vaccination. Disease activity and therapies were also evaluated. Results Before immunization, SLE and HC groups had high SP rates (89% vs 77%, p = 0.061) and elevated GMT titer with higher levels in SLE (129.1(104.1-154.1) vs 54.8(45.0-64.6), p < 0.001). Frequency of two previous years' influenza vaccination was high and comparable in SLE and HC (89% vs 90%, p = 1.000). Four weeks post-vaccination, median GMT increased for both groups and remained higher in SLE compared to HC (239.9(189.5-290.4) vs 94.5(72.6-116.4), p < 0.0001) with a comparable FI-GMT (2.3(1.8-2.9) vs 1.9(1.5-2.3), p = 0.051). SC rates were low and comparable for both groups (16% vs 11%, respectively, p = 0.974). Disease activity scores remained stable throughout the study (p = 1.000) and severe adverse events were not identified. Conclusion Influenza A/Singapore (H3N2) vaccine has an adequate safety profile. The distinct immunogenicity pattern from other influenza A components characterized by a remarkably high pre- and post-vaccination SP rate and high GMT levels may be associated with previous influenza A vaccination. (, NCT03540823). (AU)

• FAPESP's process: 18/09937-9 - Analysis of the immune profile of saliva and serum of patients with primary Sjogren's Syndrome
• Grantee: Victor Adriano de Oliveira Martins
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
• FAPESP's process: 17/14352-7 - Assessment of relevance of blood levels of drugs in the monitoring rheumatic autoimmune diseases: safety, effectiveness and adherence to therapy
• Grantee: Tatiana Do Nascimento Pedrosa
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 10/10749-0 - Anti-influenza H1N1/2009 vaccine in autoimmune rheumatic diseases patients
• Grantee: Eloisa Silva Dutra de Oliveira Bonfá
• Support Opportunities: Regular Research Grants
• FAPESP's process: 15/03756-4 - Assessment of relevance of blood levels of drugs in the monitoring rheumatic autoimmune diseases: safety, effectiveness and adherence to therapy
• Grantee: Eloisa Silva Dutra de Oliveira Bonfá
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 18/16162-3 - Yellow fever and influenza 2018 vaccination campaign: safety and immunogenicity in patients with rheumatological autoimmune diseases
• Grantee: Eduardo Ferreira Borba Neto
• Support Opportunities: Regular Research Grants